Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;183(2):202-203.
doi: 10.1111/bjd.18848. Epub 2020 Jan 14.

Repurposing existing trial data to infer relative efficacy of biologics: guselkumab vs. ustekinumab for psoriasis

Z Z N Yiu  1
Affiliations
Comment

Repurposing existing trial data to infer relative efficacy of biologics: guselkumab vs. ustekinumab for psoriasis

Z Z N Yiu. Br J Dermatol. 2020 Aug.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Sertkaya A, Wong HH, Jessup A, Beleche T. Key cost drivers of pharmaceutical clinical trials in the United States. Clin Trials 2016; 13:117-26.
    1. Miller J, Ross JS, Wilenzick M, Mello MM. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. BMJ 2019; 366:l4217.
    1. Diels J, Thilakarathne P, Cameron C et al. Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis. Br J Dermatol 2020; 183:276-84.
    1. Langley RG, Tsai TF, Flavin S et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol 2018; 178:114-23.
    1. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665-74.

Publication types